Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT
PHASE2CompletedINTERVENTIONAL
Enrollment
19
Participants
Timeline
Start Date
April 30, 2016
Primary Completion Date
July 31, 2019
Study Completion Date
December 31, 2020
Conditions
Graft-versus-Host Disease
Interventions
DRUG
Everolimus
GvHD prophylaxis
Trial Locations (1)
50924
University of Cologne, Cologne
All Listed Sponsors
lead
University of Cologne
OTHER
NCT02812940 - Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT | Biotech Hunter | Biotech Hunter